Blue Shield of California told doctors in its program to limit the use of anemia drugs from Johnson & Johnson and Amgen because of possible links to heart attack and stroke. The insurer said doctors should wait until a patient's anemia is just short of requiring a transfusion before using Procrit, Aranesp or Epogen, although it said Procrit is the group's preferred drug.

Full Story:

Related Summaries